



Press release

Palacongressi Rimini hosts breakthrough diagnosis and treatments of breast cancer

Sentinel lymph node examination, "Dignicap" - reducing hair loss during chemotherapy, and modern breast prostheses: improving the diagnosis and treatment of breast cancer

Video interviews with Domenico Samorani and Paolo Veronesi

https://youtu.be/DNJZqyOSwfs e https://youtu.be/R7xDXT20nxE

Rimini, 27 February 2016 – Important news regarding one of the most common tumoral pathologies, which last year affected 48,000 women in Italy, was presented at the "**2nd Senology Congress on "Breast Cancer: women's health at risk**", promoted by the Paolo Onofri Association and sponsored by the Romagna Health Board and by IOR, the oncological institute of Romagna.

During the conference, held in the rooms of the **Palacongressi di Rimini**, **Paolo Veronesi**, **Director of the Breast Cancer Surgery Division of the European Institute of Oncology**, presented a new, multi-centric randomised study comparing sentinel lymph node biopsy with the simple observation in patients with small breast tumours and the confirmation of negative results from armpit ultrasounds. The first elements gathered indicate the possibility of a substantial reduction in the need for biopsies and axillary dissection, avoiding such procedures in about two thirds of cases of patients with clinically negative lymph nodes. The study was carried out on 1,300 women. It is therefore evident that patients can be subject to less invasive treatments, resulting in minor costs and use of resources for the healthcare system, resorting to surgery only when necessary and inevitable.

Doctor Domenico Samorani, scientific coordinator of the convention and representative of yet another avant-garde structure of the Romagna region, Franchini Hospital in Santarcangelo, along with his state of the art Breast Cancer Division, presented delegates with the latest news, such as "Dignicap" and "ADM" prostheses: "Dignicap' is a new device capable of preventing or reducing hair loss in women undergoing chemotherapy. It is one of the most obvious negative and invasive effects and I sincerely hope that companies, associations and private individuals help us to sustain the cost of €120,000, necessary to purchase two of these machines. The new prostheses, on the other hand, have a new ADM (a cellular dermal matirix) biological, semi-synthetic covering, which favours breast reconstruction immediately after a mastectomy, relieving the patient of many months of waiting which is still necessary for the implantation of traditional prostheses."

"Today the oncology divisions in our region are a prime example of excellence on both a national and international level - says Professor **Dino Amadori**, Congress president and **scientific director of IRST (Cancer Institute of Romagna)** - it is the result of a process born a long time ago, with the founding of the IOR in 1979. Since then, all the oncological divisions here operate as a network, enhancing synergies, research and treatment protocols. And since 2007, with the creation of the IRST, even better results have been achieved".

PRESS CONTACT

Elisabetta Vitali (Communications and Media Relations Manager Rimini Fiera), Alessandra Fiorano (Press Officer Rimini Fiera) Carlo Bozzo (Media Consultant Event & Conference BU Rimini Fiera) +39 3355778445 – carlobozzo@hotmail.com